Cannabis
Avicanna to Supply UK Market with Cannabis-Based Medicinal Products Through Distribution Agreement with the LYPHE Group
Avicanna Inc. (“Avicanna” or the “Company“) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of organic and sustainable plant-derived cannabinoid-based products, is pleased to announce that the Company has entered into an importation and distribution agreement (the “Agreement“) with Astral Health Ltd. (“Astral“), the operating subsidiary of the LYPHE Group Ltd (“LYPHE Group” or “LYPHE“) to supply its cannabis-based medicinal products (“CBMPs“) to patients in the United Kingdom under the MHRA ‘specials’ programme.
“We look forward to the opportunity to provide access to our cannabis-based medicinal formulations to a population and medical community that is seeing increased demand for quality evidence-based products, such as our proprietary research-backed formulations. Both the Astral and Avicanna teams are aligned on the long-term vision and more importantly are qualified to provide the medical community in the United Kingdom with safe, effective and superior cannabinoid-based solutions, education and training,” stated Aras Azadian, Chief Executive Officer.
Dean Friday, Chief Executive Officer of LYPHE, commented “We are very proud to be partnering with Avicanna in bringing their products to the UK market. Avicanna are market-leaders in terms of product quality, and their research-backed formulations give the company a distinct advantage in the UK market”.
Under the Agreement, Avicanna will supply Astral with CBMPs, and both Avicanna and Astral will work together to achieve key strategic milestones in the United Kingdom related to market activation, market access and safety. The parties will also work together to collaborate on medical education programs with a focus on safety, dose guidance and efficacy. The Agreement will allow Avicanna to begin generating revenue from a growing UK market, while providing patients with increased access to the life-changing medicines they require.
It is expected that the CBMPs will be prepared in Colombia using Avicanna’s proprietary research-backed formulations, using cannabis extracts from Santa Marta Golden Hemp S.A.S., a subsidiary of Avicanna, and manufactured at the facilities of Avicanna’s exclusive Colombian manufacturer, Altea Farmaceutica S.A. using Good Manufacturing Practices (GMP).
To the knowledge of the Company, it carries out its operations in compliance with all applicable laws in the jurisdictions in which it operates.
SOURCE Avicanna Inc.
Cannabis
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
Cannabis
Bay Area Social Equity Operator Launches the Purple Raina Balm Wand 1:1, an Inclusive Multipurpose Cannabis Topical
Cannabis
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
Cannabis2 weeks ago
Sannabis, Inc. (OTC: USPS) Unveils Innovative NO LICK! Terpene Spray for Cannabis Products to Enhance CBD and THC to Achieve the Entourage Effect
-
Cannabis2 weeks ago
Cannabis Concentrate Market to Cross US$2.4 Billion by 2030 amid Rising Medical and Recreational Demand
-
Innocan1 week ago
Innocan Pharma Initiates FDA Approval Process for Liposome Injection Therapy for Chronic Pain
-
Curaleaf1 week ago
Curaleaf Completes Acquisition of Northern Green Canada
-
Cannabis1 week ago
Cannabis Capsule Global Analysis Report 2024: Market to Reach $79.2 Billion in 2028 – Forecast to 2033 Featuring GW Pharmaceuticals, Trulieve Cannabis, Green Thumb Industries, Tilray, Columbia Care
-
SCHWAZZE2 days ago
Schwazze Sets First Quarter 2024 Conference Call for May 15, 2024 at 5:00 p.m. ET
-
Cannabis2 days ago
Technological Advancements in Breathalyzers Drive Market Growth and Enhance Road Safety
-
Humboldt2 days ago
Humboldt Seed Company partners with Apollo Green to bring California cannabis genetics to the global marketplace